Purpose: To assess the efficacy of triple combination therapy (TCT) including bevacizumab (BEV), low-fluence photodynamic therapy, and posterior sub-Tenon's triamcinolone acetonide in patients with wet age-related macular degeneration.
A ge-related macular degeneration (AMD) is the leading cause of blindness in people aged .50 years in industrialized countries. [1] [2] [3] Neovascular (wet) AMD results from abnormal blood vessels growing in and under the retina, and although it represents only 10% to 20% of all cases of AMD, it accounts for 80% to 90% of AMD-associated vision loss. 4 There are now a variety of treatment options that are known to be effective in suppressing growth of these vessels and improving visual acuity outcomes. Recent AMD studies have not only compared the various treatment options individually but also have explored the possible benefits of combining therapies to target the multiple steps in the pathogenesis of AMD. A combination approach in treating the age-related inflammation that stimulates choroidal neovascularization (CNV), the angiogenic agent stimulating CNV growth, and the CNV itself might be most effective in treatment of wet AMD. This study explores the efficacy of a triple combination therapy (TCT) in improving patient vision and decreasing subretinal exudation while also appearing to require few subsequent retreatments.
Photodynamic therapy (PDT) with verteporfin (Visudyne; CIBA Vision Corp, Duluth, GA) has been found to be effective in the treatment of predominantly classic subfoveal CNV in patients with AMD. 5 Photodynamic therapy reduces the probability of moderate and severe vision loss but often requires continued retreatment over time because of a high CNV recurrence rate. 6 Low-fluence models of PDT (LF PDT) with verteporfin also have been proven to be effective in reducing vision-loss because of CNV. 7 More recently, studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the development of CNV, 8 and as such, alternative antiangiogenic treatment options have been developed and implemented against wet AMD.
9 These antiangiogenic agents have improved patient visual and anatomical outcomes compared with PDT. 10 One such anti-VEGF agent, bevacizumab, a full-length humanized anti-VEGF antibody, has grown in clinical popularity in the treatment of CNV. Bevacizumab has been shown to possess a prolonged duration of action compared with other anti-VEGF agents, such as ranibizumab, leading to less frequent intravitreal injections with similar functional and anatomical outcomes. [11] [12] [13] However, like other anti-VEGF monotherapy treatment options, bevacizumab typically requires multiple rounds of injections every 4 weeks to 6 weeks to maintain efficacy both functionally and anatomically. 14, 15 Decreasing the number of treatments would also diminish the risk of complications from intravitreal injections, like endophthalmitis and complications of the posterior segment, and reduce the associated costs of monthly injections.
Another recent approach to the treatment of exudative AMD had been the use of intraocular or periocular corticosteroids, such as triamcinolone acetonide (TA). Triamcinolone acetonide has been used for indications ranging from uveitis to cystoid macular edema and recently also has been used in the treatment of diabetic macular edema and retinal vein occlusions. 16, 17 Clinical trials comparing intravitreal TA monotherapy with intravitreal bevacizumab in the treatment of neovascular AMD have shown that the corticosteroid on its own elicits limited improvement in visual acuity accompanied with a significant risk of increased intraocular pressure. 18 For diseases such as neovascular AMD that involve the choroid, recent studies also suggest that sub-Tenon's delivery of TA (posterior sub-Tenon's triamcinolone acetonide [PSTA]) may be a safer treatment method compared with intravitreal injection 19 ; however, studies of PSTA efficacy in patients with wet AMD have been inconclusive with Kim et al 20 finding encouraging results in monotherapy, and Gilson et al 21 finding limited efficacy when PSTA was used in conjunction with PDT. 22 Transscleral delivery of the drug has shown a diverse set of results during investigations comparing vitreous concentration of the drug after sub-Tenon's placement, with some studies showing comparable concentrations and others showing significantly lower concentrations of TA after subTenon's introduction. 20, 23, 24 We previously reported that 40 mg of PSTA achieved therapeutic levels in the vitreous (111 ng/mL before reaching a plateau at 20-25 ng/mL) up to 1 month after delivery. 25 Recently, studies of combination therapy in the treatment of neovascular AMD have become increasingly common. The most current wet AMD treatment methods using TA involve it in combination with another therapy rather than as a monotherapy itself, usually either PDT 26, 27 or an intravitreal antiangiogenic agent. 28 Similarly, other studies have also investigated combination treatment with PDT and bevacizumab in combating the multifaceted pathogenesis of neovascular AMD. 29, 30 By extending the same logic that led to dual combination therapies, namely that each treatment targets a different step in the pathogenesis of wet AMD, TCT may prove even more effective against CNV. Triple combination therapy eliminates CNV via LF PDT, downregulates VEGF with antiangiogenic agents, and uses TA to decrease the inflammation that is one cause of AMD angiogenesis. 31 Early studies of TCT have used PDT, bevacizumab, and dexamethasone, 32 as well as PDT, bevacizumab, and intravitreal TA. 31, 33 Generally, these TCTs have shown improvement in visual acuity outcomes and a decrease in the need for subsequent retreatment compared with monotherapeutic approaches.
We hypothesized that TCT involving LF PDT, intravitreal bevacizumab, and PSTA would demonstrate significant functional and anatomical efficacy in patients with wet AMD throughout a long follow-up period after initial treatment. Unlike previous studies, we assessed anatomical outcomes with retinal thickness data acquired via optical coherence tomography (OCT). This combinatorial approach could further reduce the total number and frequency of procedures undergone by the patient while still improving visual acuity outcomes and limiting associated complication risks and treatment costs. To our knowledge, our TCT protocol is the only one that incorporates a sub-Tenon's delivery of TA and one of few using longer-acting TA rather than the shortacting dexamethasone.
Methods
The protocol for this retrospective study was submitted to and approved by the Beth Israel Deaconess Medical Center Internal Review Board before any analysis began. This was a consecutive case series study, and as such, all patients with neovascular AMD receiving TCT at the Division of Ophthalmology at the Beth Israel Deaconess Medical Center between June 2004 and November 2008 were included in the data set.
Twenty-six treatment-naive eyes received TCT consisting of intravitreal bevacizumab injection, LF PDT with verteporfin, and PSTA injection. We also compared the 26 treatment-naive eyes that underwent TCT with 5 other eyes receiving TCT that had already received previous treatment for wet AMD.
Intravitreal bevacizumab injections were superotemporal with the same volume and injection protocol used for all injections. Briefly, a cotton tip was soaked in proparacaine 0.5% and then placed under the lid in the superotemporal quadrant of the eye for 5 minutes, with 1 drop of a fourth-generation fluoroquinolone given ever topically every 3 minutes 3 times a day. The injection site was prepared with a 10% povidone-iodine swab after a lid speculum was inserted, and finally, a 30-gauge needle was used for the injection of 1.25 mg of bevacizumab.
Posterior sub-Tenon's injections were performed immediately after intravitreal bevacizumab injection for all eyes that underwent TCT. The procedure for posterior sub-Tenon's injection is described in greater detail by Nozik. 34 After the application of topical anesthetic and antibiotic as described for the intravitreal bevacizumab injection, a 3/4-inch 25-gauge needle on a 1-mL syringe was placed in the fornix superotemporally with the bevel toward the globe. The tip was moved side to side while also being moved posteriorly along the sclera until it was positioned directly behind the macula. During the introduction of the needle, the limbal vessels were watched carefully for synchronous lateral movements that might indicate potential engagement of the needle with the sclera. Forty milligrams of TA were then injected slowly into the sub-Tenon's space.
The PDT component of TCT was conducted at the Massachusetts Eye and Ear Infirmary 18.4 6 16 days after initial diagnosis of neovascular wet AMD, always after the intravitreal bevacizumab and PST TA injections were performed. Patients undergoing PDT had an injection of verteporfin, followed by low-fluence laser carried out per the VIM study protocol. 7 Patient information was collected in a Microsoft Excel spreadsheet (Microsoft, Redmond, WA). Demographic information tabulated in this data set included gender, history of smoking, nonocular medical histories, study eye, and date of neovascular wet AMD onset. Snellen visual acuity was recorded at each subsequent visit and compared with a baseline measurement obtained before initial treatment. The visual acuities were converted to logarithm of the minimum angle of resolution (logMAR) for analysis, and the net improvement in visual acuity at the conclusion of study follow-up and the change in visual acuity from baseline at 3, 6, and 12 months after treatment for each treatment arm were recorded. The 3-, 6-, and 12-month time points were measured as 13 6 5, 26 6 7, and 52 6 10 weeks, respectively, to ensure no overlap between time point groups and inclusion of the most data possible. Length of follow-up was recorded, as well as the need for any subsequent retreatment for neovascular wet AMD in the study eye. A Kaplan-Meier survival analysis was used to assess the need for subsequent retreatment in the TCT group as another primary outcome measurement. Complication rates were also recorded to compare the treatment arms, most notably any change in intraocular pressure from baseline .4 mmHg after PSTA injection.
Treatment efficacy was also evaluated by change in central foveal retinal thickness as recorded on Stratus OCT (OCT 3000; Carl Zeiss Meditec, Dublin, CA) compared with a pretreatment baseline. Fast macular thickness maps were performed on OCT to calculate central foveal thickness. Monitoring the OCT fundus image during the scan process ensured that the scans obtained were in fact transmacular when patients lacked normal foveal contour.
Statistical analyses were performed using StatView 5 for Macintosh and Windows (SAS Institute, Inc, Cary, NC) and SPSS software version 12.0 for Windows (SPSS, Inc, Chicago, IL). Paired t-tests were used to compare baseline findings and those after treatment with significance deemed to be P , 0.05.
Results
On average, the 26 study eyes undergoing TCT were found to improve in visual acuity from a 20/243 Snellen baseline to 20/218 over a follow-up period of 56.7 6 28.1 weeks, although this net difference in visual acuity was not statistically significant (P = 0.2131). Measured from baseline until the conclusion of their respective follow-up period, 19 eyes that underwent TCT (73.1%) showed either no loss or improvement in visual acuity. As seen in Figure 1 , at a time point 3 months after initial treatment, eyes that underwent TCT showed an improvement of 0.140 6 0.273 logMAR (n = 23), 0.182 6 0.383 logMAR at 6 months (n = 20), and 0.077 6 0.285 logMAR at 12 months (n = 17). The changes in vision at 3 months and 6 months were statistically significant with P values of 0.0219 and 0.0470, respectively. At 3 months, 20 eyes (87%) showed either no loss or improvement in visual acuity, 15 eyes (75%) had no loss or improvement at 6 months, and 12 eyes (71%) had no loss or improvement at 12 months. Eyes that underwent TCT that did not receive retreatment at any point during their follow-up showed a mean improvement in visual acuity from 0.140 6 0.273 logMAR at 3 months (n = 23), 0.157 6 0.414 logMAR at 6 months (n = 15), and 0.242 6 0.224 logMAR at 12 months (n = 7).
The 18 eyes that underwent TCT with sufficient OCT data showed a significant decrease (P = 0.0008) in retinal thickness of 2102.5 6 102.9 mm from their initial baseline central retinal thickness (330.7 mm) to the end of their follow-up period. As seen in Figure 2 , at 3 months, the change in central retinal thickness from baseline in eyes that underwent TCT was 2123.8 6 102.7 mm (n = 15), followed by 287.7 6 99.8 mm at 6 months (n = 13) and 2101.6 6 103.3 mm at 12 months (n = 10). Untreated eyes that underwent TCT showed changes of 2123.8 6 102.7 mm at 3 months (n = 15), 2106 6 114.6 mm at 6 months (n = 9), and 298. 8 6 142 .0 mm at 12 months (n = 5). All these changes in central retinal thickness from baseline were statistically significant (P = 0.0029, 0.0081, and 0.0125, respectively).
The duration of TCT efficacy was also measured via Kaplan-Meier analysis, with subject survival classified as subsequent retreatment occurring after the initial treatment regimen. At 1 year after initial therapy, eyes that underwent TCT had a survival rate of 62.1 6 10.8 ( Figure 3 ). In total, 13 of 26 eyes that underwent TCT (50%) needed retreatment by the conclusion of their respective follow-ups. At the 3-month time point, only 4 of 24 eyes with sufficient data (16.7%) required retreatment, while 9 of 22 eyes (40.9%) required retreatment by 6 months and 11 of 18 eyes (61.1%) required retreatment by 12 months.
None of the differences in the demographic data was found to be statistically significant. Three patients (9.7%) treated with TA during TCT had an increase in intraocular pressure .4 mmHg compared with pretreatment baseline levels, with one of these patients Fig. 1 . Change in visual acuity from baseline initial treatment. This graph shows the change in visual acuity (logMAR) from baseline at time points 3, 6, and 12 months after initial TCT. The improvement in visual acuity for all the eyes that underwent TCT at time points 3 months and 6 months was significant (P = 0.0219 and 0.0470, respectively), while that was not the case at 12 months (P = 0.1918). The difference between those with retreatment and those without at 12 months indicates the end of initial efficacy of TCT for many patients between the 6-month and the 12-month time points. The first n value at each x-axis point corresponds to the TCT group, and the second n value corresponds to the TCT without retreatment group. This graph shows the change in central foveal retinal thickness from baseline in micrometers as measured by Stratus OCT at time points 3, 6, and 12 months after initial treatment. Patients who did not receive an OCT initially at the time of treatment were not included, nor were those who lacked OCT measurements throughout the follow-up period at the specified time intervals. The first n value at each x-axis point corresponds to the TCT group, and the second n value corresponds to the TCT without retreatment group. 
Discussion
Our retrospective results show that TCT achieves marked functional and anatomical improvement in patients with neovascular AMD, in many cases lasting over a year after initial treatment. The discrepancy between the 3-, 6-, and 12-month follow-up data and the net visual acuity improvement supports the transient action of bevacizumab therapy because many patients at some point achieved significant visual acuity improvement, which was eventually lost by the conclusion of the follow-up period. Despite constantly monitoring for CNV after initial treatment, new CNV developed during the follow-up phase that could potentially deteriorate visual acuity below baseline levels. As a result of this new CNV, any improvement that may have been seen for most of the follow-up period might not be reflected in the net visual acuity measurements.
Through the standardized time point analysis, we were able to uncover that the majority of vision loss occurred between 6 months and 12 months after initial treatment, which might possibly be a product of diminished efficacy with time as has already been suggested with bevacizumab therapies. The later decline in vision could also be a product of the variance in follow-up duration and frequency, with patients having longer gaps between follow-ups later in the study and thus possibly returning with worse progression of their lesions. The variability in the time between the injections and the LF PDT for patients undergoing TCT (18.4 6 16 days) may also have contributed to the apparent elongation of the therapy's duration of action. Although limited by these shortcomings, our study indicates that TCT achieves visual acuity improvement, which is sustained for a long duration as evidenced by the net change in visual acuity data and the 3-, 6-, and 12-month follow-up time points. Other studies have supported the finding of bevacizumab monotherapy's limited duration of action compared with TCT, but prospective studies charting the duration of action of anti-VEGF in monotherapy and in combination therapy are needed. 27, 31 To date, few TCT studies have included an analysis of retinal thickness. We found that TCT elicited a significant change in retinal thickness as measured by OCT, although these patients started with a large mean initial thickness (330.7 mm), which left significant room for anatomical improvement. The statistical significance of our anatomical results extending out to 12 months suggests that the multimodal treatment approach might elicit greater anatomical results than other known therapies, most likely because of the diverse pathogenesis of the disease itself. Bakri et al 32 found similar changes in retinal thickness through TCT with dexamethasone, although their study also lacked a monotherapy control group. The large net and maximum improvement in central foveal retinal thickness and maximum visual acuity could in part be ascribed to the notably poor baseline visual acuity and retinal thickening for eyes that underwent TCT, which left greater room for improvement and concordantly an artificially inflated statistical efficacy. Such poor baseline visual acuity and OCT values are largely a product of the retrospective nature of this study and should be eliminated in future prospective trials.
The difference in visual acuity between eyes that required retreatment during follow-up and those that did not highlights the potential of TCT to deliver longlasting functional efficacy. It is possible that there are particular types of presenting lesions that respond best to TCT as opposed to monotherapeutic intervention. A randomized prospective trial would help to control for, and deliver understanding about, the effects of differences in presenting lesion on TCT short-and long-term efficacy.
The results also show a general correlation between anatomical outcomes and functional outcomes Fig. 3 . Kaplan-Meier analysis of TCT. Black points (event times) on the graph indicate subsequent retreatment after initial TCT in treatment-naive eyes. Gray points (censor times) indicate patients who reached the conclusion of their follow-up period without receiving retreatment. Time is measured in weeks. Of note is that even 1 year after treatment, the treatment group still had a cumulative survival rate of 62.1 6 10.8%.
comparing change in central foveal retinal thickness as measured by OCT with that in visual acuity. However, this general trend was not found to be statistically significant. Recent studies of the correlation between anatomical and functional outcomes in patients with subfoveal CNV have also shown limited statistical significance. 35 Given recent concerns regarding retinal thinning and neural cell death with the long-term use of anti-VEGF agents for neovascular AMD, 36 further investigations with prolonged follow-up after antiangiogenic therapy consisting of both visual acuity and OCT data are certainly warranted.
As seen in other studies on the efficacy of combination therapy, TCT required few treatments as measured by the percentage of eyes requiring retreatment and Kaplan-Meier analysis. 31 Our net treatmentnaive TCT retreatment percentages (50% net after a mean follow-up of 56.7 weeks, 16.7% at 3 months, and 40.9% at 6 months) were in between the results of previous studies. Yip et al 31 found 22% at both 3 months and 6 months, while Ahmadieh et al 33 found 58.8% at 3 months. Intravitreal TA injections were used by Yip et al and Ahmadieh et al, 33 with a high dosage of TA by Yip et al 31 possibly explaining the discrepancy in retreatment frequencies. Other studies suggest that PDT risks inducing recurrent CNV by aggravating choroidal ischemia and leading to increased expression of VEGF. 31, 37 Kaplan-Meier analysis showing a 62.1 6 10.8% survival rate at 1 year after initial treatment further demonstrates the potential of TCT to reduce the number of necessary treatments compared with antiangiogenic therapy or PDT, which have already been shown to be transient in their action or induce CNV recurrence, respectively.
A group of 5 previously treated eyes undergoing TCT were compared with the 26 eyes that underwent TCT. Like treatment-naive eyes, previously treated eyes undergoing TCT also showed a net improvement in visual acuity (0.0356 logMAR); however, they had a significantly better initial visual acuity (20/80.3 vs. 20/242.6). Both groups achieved similar decreases in central retinal thickness with treatment naive decreasing 2102.5 mm and previously treated decreasing 262.7 mm. Previously treated eyes showed slightly better survival rates during Kaplan-Meier analysis, with a 1-year survival rate of 75.0 6 21.7%, with only 1 patient requiring retreatment in the first year of followup. The small size of this group and the difference in initial visual acuity limit definitive comparison.
Consistent with other studies involving the use of TA in the treatment of wet AMD, a few cases of significantly increased intraocular pressure were noted during the follow-up period. 16, 18 However, only one needed antiglaucoma drops for resolution. Some patients were excluded from the TCT regimen because of family history of glaucoma or already elevated intraocular pressures. The lack of other complications in each treatment group demonstrates that, with proper observation during screening and follow-up, TCT including PSTA should carry only slightly elevated risk for the patient during initial treatment. Furthermore, it also holds less risk during the follow-up phase when fewer retreatments are necessary. Yip et al 31 suggested that the use of dexamethasone, which has a much shorter half-life than TA, may have fewer side effects when used in TCT, although this has not been fully investigated yet. A second intravitreal injection with dexamethasone would double the risks of endophthalmitis and might be associated with an increase in intraocular pressure. Based on the limited number of complications from PST TA use in this study compared with its potential benefit in TCT, further research into the pharmacokinetics of posterior sub-Tenon's delivery of TA is necessary to evaluate its comparative efficacy and benefits versus intravitreal delivery.
Looking across the various modes of analysis, TCT does appear to be an anatomically and functionally effective means of treating neovascular AMD, but the heterogeneity of the present study's data makes definitive claims difficult to support. Insufficient numbers of patients undergoing TCT who had also been previously treated for wet AMD make drawing conclusions tenuous in comparisons with treatmentnaive patients. A more consistent follow-up period, classification of the various lesion types, and inclusion of more patients who underwent TCT with previous treatment would improve the utility of future studies. Our results show promising functional and anatomical efficacy often without need for immediate retreatment; however, further prospective randomized studies comparing TCT with bevacizumab and/or LF PDT monotherapies are necessary to further elucidate the possible risks, benefits, and mechanism of action of TCT in patients with neovascular AMD.
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